Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNM2 lipid binding drives centronuclear myopathy and represents a potential therapeutic target.

JCI insight - 8 May 2026

Gómez-Oca Raquel, Massana-Muñoz Xènia, Reiss David, De Carvalho Neves Juliana, Diedhiou Nadege, Silva-Rojas Roberto, Cowling Belinda S, Goret Marie, Laporte Jocelyn

Abstract excerpt

Centronuclear myopathies (CNMs) are rare congenital disorders characterized by muscle weakness, fiber hypotrophy, and organelle mislocalization. Most cases arise from mutations in MTM1 or DNM2, encoding myotubularin and dynamin-2, respectively. DNM2 is a GTPase that binds lipids, oligomerizes around membranes, and mediates fission. We previously showed that DNM2 levels are elevated in MTM1-CNM patients and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Models, Animal
Share to Dynamin II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNM2 gene

Share to Muscle, Skeletal

Share to Mutation

Share to Myopathies, Structural, Congenital

Share to Protein Tyrosine Phosphatases, Non-Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 42100875
DOI: 10.1172/jci.insight.204423
PMCID: PMC13232018

Genes

DNM2
MTM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNM2 lipid binding drives centronuclear myopathy and represents a potential therapeutic target.PMID 42100875Read ↗

DNM2 levels normalization improves muscle phenotypes of a novel mouse model for moderate centronuclear myopathySemantic proximity Read ↗

MTM1 overexpression prevents and reverts BIN1-related centronuclear myopathy.Semantic proximity Read ↗

Reducing dynamin 2 expression rescues X-linked centronuclear myopathy.Semantic proximity Read ↗

Muscle-specific function of the centronuclear myopathy and Charcot-Marie-Tooth neuropathy-associated dynamin 2 is required for proper lipid metabolism, mitochondria, muscle fibers, neuromuscular junctions and peripheral nerves.Semantic proximity Read ↗

The myopathy-causing mutation DNM2-S619L leads to defective tubulation in vitro and in developing zebrafish.Semantic proximity Read ↗

Reducing dynamin 2 (DNM2) rescues DNM2 -related dominant centronuclear myopathySemantic proximity Read ↗

Mice with muscle-specific deletion of Bin1 recapitulate centronuclear myopathy and acute downregulation of dynamin 2 improves their phenotypes.Semantic proximity Read ↗

A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice.Semantic proximity Read ↗

Dynamin-2 mutations associated with centronuclear myopathy are hypermorphic and lead to T-tubule fragmentation.Semantic proximity Read ↗

Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin.Semantic proximity Read ↗

Differential impact of ubiquitous and muscle dynamin 2 isoforms in muscle physiology and centronuclear myopathy.Semantic proximity Read ↗

Increased expression of wild-type or a centronuclear myopathy mutant of dynamin 2 in skeletal muscle of adult mice leads to structural defects and muscle weakness.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.